Pfizer makes moves to acquire Seagen in potential $30B+ deal
Pfizer is in talks to acquire cancer drugmaker Seagen in a deal that could be worth more than $30 billion, after acquisition talks between Merck and the biotech broke down last year, the Wall Street Journal reported Sunday night.
A potential deal between Pfizer and Seagen isn’t a guarantee and the talks are still at an early stage, the WSJ reported, citing people familiar with the matter. Representatives for Seagen and Pfizer declined to comment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.